n Cardiovascular Journal of South Africa - FDA approves losartan for stroke prevention in hypertensive patients with LVH : drug trends in cardiology
|Article Title||FDA approves losartan for stroke prevention in hypertensive patients with LVH : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of South Africa|
|Publication Date||May 2005|
Extracted from text ... 176 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 3, May/June 2005 FDA approves losartan for stroke prevention in hypertensive patients with LVH Losartan (Cozaar Comp(r)) has recently been approved by the FDA for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy. The new indication for reduc tion in stroke is based on the landmark LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study.1 Cozaar Comp(r) (losartan potassium- hydrochlorothiazide tablets) and Cozaar are the only angiotensin II receptor blockers (ARBs) to be indicated for stroke reduction in this setting. Cozaar Comp(r) is the fixed-dose combination ..
Article metrics loading...